Epharmix Revenue and Competitors
Estimated Revenue & Valuation
- Epharmix's estimated annual revenue is currently $14.1M per year.
- Epharmix's estimated revenue per employee is $243,000
Employee Data
- Epharmix has 58 Employees.
- Epharmix grew their employee count by 21% last year.
Epharmix's People
Name | Title | Email/Phone |
---|---|---|
1 | Chief Developer | Reveal Email/Phone |
2 | CEO | Reveal Email/Phone |
3 | Creative Director | Reveal Email/Phone |
4 | Graphic Designer | Reveal Email/Phone |
5 | Growth Engineer | Reveal Email/Phone |
Epharmix Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $9.3M | 43 | 54% | N/A | N/A |
#2 | $520.1M | 1376 | 4% | N/A | N/A |
#3 | $8.9M | 41 | -5% | N/A | N/A |
#4 | $9.5M | 44 | 10% | N/A | N/A |
#5 | $21.9M | 81 | 7% | N/A | N/A |
#6 | $4M | 21 | -52% | N/A | N/A |
#7 | $36.5M | 135 | 2% | N/A | N/A |
#8 | $13.1M | 54 | 13% | N/A | N/A |
#9 | $7.6M | 35 | 9% | N/A | N/A |
#10 | $25.1M | 93 | 6% | N/A | N/A |
What Is Epharmix?
Epharmix helps your care management team improve health outcomes by engaging high and rising-risk patients. Our scalable, automated call and text platform collects patient-reported health status between regular visits to identify rising-risk patients, enabling your clinical team to prevent costly hospitalizations or exacerbations. We support 24 chronic and behavioral health conditions, offering a holistic approach to addressing co-morbidities with one evidence-based tool that is aligned with quality metrics to meet your organizations evolving business goals. Self-guided Demo: https://try.epharmix.com/ Learn More: https://www.epharmix.com/
keywords:N/AN/A
Total Funding
58
Number of Employees
$14.1M
Revenue (est)
21%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $16.9M | 58 | 4% | N/A |
#2 | $14.3M | 59 | 4% | N/A |
#3 | $13M | 59 | 7% | N/A |
#4 | $13.5M | 60 | 5% | N/A |
#5 | $14.6M | 60 | 2% | N/A |